CancerDrs

Lung Cancer clinical trials in Oregon

37 actively recruiting lung cancer trials at 19 sites across Oregon.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Oregon:
  • Legacy Mount Hood Medical Center — Gresham, Oregon
  • Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
  • Legacy Meridian Park Hospital — Tualatin, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Oregon:
  • Northwest Cancer Specialists, P.C — Happy Valley, Oregon
  • Northwest Cancer Specialists, P.C. — Portland, Oregon
  • Northwest Cancer Specialists, P.C — Tigard, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer …

Sponsor: Bayer
NCT ID: NCT06452277
Sites in Oregon:
  • Providence Cancer Institute - Franz Clinic — Portland, Oregon
  • Providence Oncology and Hematology Care Clinic Westside — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in Oregon:
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Newberg Medical Center — Newberg, Oregon
  • Providence Willamette Falls Medical Center — Oregon City, Oregon
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Oregon:
  • Providence Portland Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Oregon:
  • USOR Oncology Associates of Oregon, P.C. — Eugene, Oregon
  • Compass Oncology - Rose Quarter — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a…

Sponsor: Synthekine
NCT ID: NCT05098132
Sites in Oregon:
  • Providence Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Oregon:
  • Oregon Health & Science University (OHSU) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RA…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07397338
Sites in Oregon:
  • OHSU Knight Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side e…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07154290
Sites in Oregon:
  • Oregon Health and Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection…

Sponsor: Genprex, Inc.
NCT ID: NCT05703971
Sites in Oregon:
  • Willamette Valley Cancer Institute (Oregon) — Eugene, Oregon
  • Northwest Cancer Specialists, P.C. — Portland, Oregon
  • Providence Cancer Institute — Portland, Oregon
  • Northwest Cancer Specialists, P.C. — Portland, Oregon
  • Northwest Cancer Specialists, P.C. — Tigard, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) trea…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07227597
Sites in Oregon:
  • Providence Cancer Institute, Franz Clinic - Eastside ( Site 0107) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer o…

Sponsor: Gilead Sciences
NCT ID: NCT06303505
Sites in Oregon:
  • Asante Rogue Region al Medical Center — Medford, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a per…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07221474
Sites in Oregon:
  • Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025) — Corvallis, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy can…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06780137
Sites in Oregon:
  • Providence Portland Medical Center ( Site 1101) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of DS-3939a in Participants With Solid Tumors

The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.

Sponsor: Daiichi Sankyo
NCT ID: NCT07739966
Sites in Oregon:
  • Oregon Health & Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth fa…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07586202
Sites in Oregon:
  • Providence Cancer Center — Portland, Oregon
  • Providence Oncology and Hematology Care Clinic Westside — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to nearby tissu…

Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT05705492
Sites in Oregon:
  • OHSU Knight Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Oregon:
  • Providence Cancer Institute Franz Clinic — Portland, Oregon
  • Providence Oncology and Hematology Care Clinic - Westside — Portland, Oregon
  • Providence St. Vincent Medical Center- Investigational Drug Services — Portland, Oregon
  • Providence St. Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →

Showing 25 of 37 trials with sites in Oregon. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09